Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Wheatley-Price, K. Ding, L. Seymour, G. Clark, F. Shepherd (2008)
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14
M. Hamilton, J. Wolf, J. Rusk, S. Beard, G. Clark, K. Witt, P. Cagnoni (2006)
Effects of Smoking on the Pharmacokinetics of ErlotinibClinical Cancer Research, 12
R. Lilenbaum, R. Axelrod, Sachdev Thomas, A. Dowlati, L. Seigel, D. Albert, K. Witt, David Botkin (2008)
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 6
D. Jackman, B. Yeap, N. Lindeman, P. Fidias, M. Rabin, J. Temel, A. Skarin, M. Meyerson, A. Holmes, A. Borras, B. Freidlin, P. Ostler, J. Lucca, T. Lynch, B. Johnson, P. Jänne (2007)
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 7
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
Wenjian Zhang, L. Siu, M. Moore, E. Chen (2005)
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 814 1
J. Baselga, C. Arteaga (2005)
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
N. Yamamoto, A. Horiike, Y. Fujisaka, H. Murakami, T. Shimoyama, Y. Yamada, T. Tamura (2008)
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsCancer Chemotherapy and Pharmacology, 61
R. Foley, A. Collins (2007)
End-stage renal disease in the United States: an update from the United States Renal Data System.Journal of the American Society of Nephrology : JASN, 18 10
V. Pollack, D. Savage, Deborah Baker, Konstantinos Tsaparikos, D. Sloan, J. Moyer, E. Barbacci, L. Pustilnik, T. Smolarek, John Davis, M. Vaidya, L. Arnold, J. Doty, K. Iwata, M. Morin (1999)
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.The Journal of pharmacology and experimental therapeutics, 291 2
M. Hidalgo, D. Bloedow (2003)
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).Seminars in oncology, 30 3 Suppl 7
S. Nakai, I. Masakane, T. Akiba, T. Shigematsu, K. Yamagata, Yuzo Watanabe, K. Iseki, N. Itami, T. Shinoda, K. Morozumi, T. Shoji, S. Marubayashi, Osamu Morita, N. Kimata, T. Shoji, Kazuyuki Suzuki, K. Tsuchida, H. Nakamoto, T. Hamano, A. Yamashita, K. Wakai, Atsushi Wada, Y. Tsubakihara (2008)
Overview of Regular Dialysis Treatment in Japan as of 31 December 2006Therapeutic Apheresis and Dialysis, 12
J. Moyer, E. Barbacci, K. Iwata, L. Arnold, B. Boman, A. Cunningham, Catherine DiOrio, Jonathan Doty, M. Morin, M. Moyer, M. Neveu, V. Pollack, L. Pustilnik, M. Reynolds, D. Sloan, A. Theleman, P. Miller (1997)
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.Cancer research, 57 21
Antonius Miller, D. Murry, K. Owzar, D. Hollis, L. Lewis, H. Kindler, J. Marshall, M. Villalona-Calero, M. Edelman, R. Hohl, S. Lichtman, M. Ratain (2007)
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 21
P. Maisonneuve, L. Agodoa, R. Gellert, J. Stewart, G. Buccianti, A. Lowenfels, R. Wolf, E. Jones, Alex Dsiney, D. Briggs, M. Mccredie, P. Boyle (1999)
Cancer in patients on dialysis for end-stage renal disease: an international collaborative studyThe Lancet, 354
C. Gridelli, P. Maione, D. Galetta, A. Rossi (2007)
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2 1
P. Hesketh, K. Chansky, A. Wozniak, F. Hirsch, A. Spreafico, J. Moon, P. Mack, B. Marchello, W. Franklin, J. Crowley, D. Gandara (2008)
Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2Journal of Thoracic Oncology, 3
ORIGINAL ARTICLE Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis Yosuke Togashi, MD,* Katsuhiro Masago, MD, PhD,* Masahide Fukudo, PhD,† Tomohiro Terada, PhD,† Yasuaki Ikemi, BPharm,† Young Hak Kim, MD,* Shiro Fujita, MD, PhD,‡ Kaoru Irisa, MD,* Yuichi Sakamori, MD,* Tadashi Mio, MD, PhD,* Ken-ichi Inui, PhD,† and Michiaki Mishima, MD, PhD* atients with chronic renal failure (CRF) undergoing he- Introduction: Although erlotinib, an orally active and selective Pmodialysis (HD) are potentially at increased risk of cancer tyrosine kinase inhibitor of epidermal growth factor receptor, is for several reasons including the presence of chronic infec- mainly metabolized in the liver, its effectiveness and safety for tion, weakened immune system, nutritional deficiencies, and patients with chronic renal failure (CRF) undergoing hemodialysis altered DNA repair. Although it is uncertain that patients (HD) has not been reported. Thus, we investigated the pharmacoki- with CRF undergoing HD are at risk for lung cancer, more netics (PK) of erlotinib and its active metabolite OSI-420 in such patients undergoing HD will be diagnosed with lung cancer patients with nonsmall cell lung cancer (NSCLC). because recent advances in HD have resulted
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: May 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.